This is not baseball, asides from the multiple analogies, you do not have to swing at absolutely anything.
Uh, you don't have to swing at everything in baseball, take enough passes and it's called either a Walk or a Strike Out.
The dual possibilities are something to think about.
Our Danish Ham[let] is correct when he questions:
Therefore it is ok to say a drug that is yet to deliver results in a pivotal trial 100% works.
100% works would imply that those yet to be seen readouts and detailed data gets filed and accepted as an NDA and subsequently receives marketing approval.
Fact is the proof that 273 works for alz is far lower than SAVA's. One nonblinded p2a trial of 32 people. SAVA is a virtual data mountain in comparison,
We have pretty good convincing data for RETT, and for PDD. They would seem to indicate that 273 has some efficacy.
For alz, that kind of data does not exist for 273. Hence the market's refusal to put that in the stock capitalization.
Instead we are capitalized as a Rett/PDD play only.
Only one way to change that...p3 alz data.
Market Data 
Markets 
